OBJECTIVE: Altered glycine and homocysteine levels may contribute to N-methyl-D-aspartate receptor dysfunction in schizophrenia. The authors measured plasma levels of these amino acids in a group of patients with chronic schizophrenia and related them to the patients' symptom profiles and types of antipsychotic medication. METHOD: Plasma levels of amino acids in 94 patients with schizophrenia were compared with those in 34 age- and sex-matched normal subjects. The Positive and Negative Syndrome Scale was used to evaluate the patients' psychopathology. RESULTS: Plasma glycine levels and glycine-serine ratios were lower and homocysteine levels were higher in patients than in comparison subjects. Low glycine levels correlated with a greater number of negative symptoms. The glycine-serine ratios of normal subjects and patients being treated with clozapine did not differ significantly. CONCLUSIONS: These findings support the hypothesis that altered levels of glycine and homocysteine may coexist in patients with schizophrenia and contribute to pathophysiological aspects of this illness.
OBJECTIVE: Altered glycine and homocysteine levels may contribute to N-methyl-D-aspartate receptor dysfunction in schizophrenia. The authors measured plasma levels of these amino acids in a group of patients with chronic schizophrenia and related them to the patients' symptom profiles and types of antipsychotic medication. METHOD: Plasma levels of amino acids in 94 patients with schizophrenia were compared with those in 34 age- and sex-matched normal subjects. The Positive and Negative Syndrome Scale was used to evaluate the patients' psychopathology. RESULTS: Plasma glycine levels and glycine-serine ratios were lower and homocysteine levels were higher in patients than in comparison subjects. Low glycine levels correlated with a greater number of negative symptoms. The glycine-serine ratios of normal subjects and patients being treated with clozapine did not differ significantly. CONCLUSIONS: These findings support the hypothesis that altered levels of glycine and homocysteine may coexist in patients with schizophrenia and contribute to pathophysiological aspects of this illness.
Authors: Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky Journal: Pharmacol Rev Date: 2008-09 Impact factor: 25.468
Authors: John E Lisman; Joseph T Coyle; Robert W Green; Daniel C Javitt; Francine M Benes; Stephan Heckers; Anthony A Grace Journal: Trends Neurosci Date: 2008-04-07 Impact factor: 13.837
Authors: Joshua T Kantrowitz; Anil K Malhotra; Barbara Cornblatt; Gail Silipo; Andrea Balla; Raymond F Suckow; Cyril D'Souza; John Saksa; Scott W Woods; Daniel C Javitt Journal: Schizophr Res Date: 2010-06-11 Impact factor: 4.939
Authors: M Föcking; L M Lopez; J A English; P Dicker; A Wolff; E Brindley; K Wynne; G Cagney; D R Cotter Journal: Mol Psychiatry Date: 2014-07-22 Impact factor: 15.992
Authors: Henry Sershen; Audrey Hashim; David S Dunlop; Raymond F Suckow; Tom B Cooper; Daniel C Javitt Journal: Neurochem Res Date: 2016-02-08 Impact factor: 3.996
Authors: Daniel C Javitt; Kevin M Spencer; Gunvant K Thaker; Georg Winterer; Mihály Hajós Journal: Nat Rev Drug Discov Date: 2008-01 Impact factor: 84.694